Navigation Links
Arena Pharmaceuticals Announces Lorcaserin Phase 2b Clinical Trial Results Published in Obesity
Date:12/8/2008

ches to the obesity epidemic," said Jack Lief, Arena's President and Chief Executive Officer. "We are confident the three ongoing lorcaserin Phase 3 trials will build on the clinical data published today, and we eagerly anticipate the announcement of our first Phase 3 data from the BLOOM trial around the end of March 2009. We expect the top-line BLOOM data will be followed by a peer reviewed presentation of the data at a conference later in the year, the announcement of BLOSSOM data in the Fall, and the submission of our New Drug Application to the FDA by the end of 2009."

A summary of results from this study were presented previously at the 2006 American Diabetes Association Scientific Sessions.

Study Design

The Phase 2b clinical trial evaluated the efficacy and safety of three doses of lorcaserin over a 12-week period in non-diabetic, obese patients. The trial was a randomized, double-blind, placebo-controlled study conducted at approximately 40 sites in the United States. The trial enrolled 469 men and women with a Body Mass Index (BMI) ranging from 30 to 45. Patients were randomized into four groups, receiving 10 mg once daily, 15 mg once daily, or 10 mg twice daily of lorcaserin, or placebo. The primary efficacy endpoint was a reduction in weight from baseline at the end of 12 weeks. There was no run-in period, and patients were counseled to maintain their usual diet and physical activity. Patients received echocardiograms at screening and the completion of the study (day 85).

Study Results

Patients completing 12 weeks of treatment with lorcaserin achieved progressive, dose-dependent and highly statistically significant weight loss of 4 pounds (1.8 kg), 5.7 pounds (2.6 kg) and 7.9 pounds (3.6 kg) at daily doses of 10 mg, 15 mg and 20 mg (10 mg twice daily), respectively, compared to weight loss of 0.7 pounds (0.3 kg) for placebo (p<0.001 for each group). Similar res
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Arena Pharmaceuticals to Present at the Piper Jaffray 20th Annual Health Care Conference
2. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
3. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
4. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
5. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
6. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
8. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
9. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
10. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
11. Arena Pharmaceuticals Announces Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014 Patients with increased inflammation, including those ... increased risk of depression. For example, a 6-month ... C virus infection causes depression in approximately 30% ... commonly known as fish oil, have a long ... of heart disease and reducing triglyceride levels. These ...
(Date:10/1/2014)... October 01, 2014 Marriagelifeinsurance.com has ... life insurance for retired couples. , Senior citizens ... financial security for their loved ones. A joint policy ... insured persons pass away. , Life insurance can ... life insurance can even be purchased online, as the ...
(Date:10/1/2014)... October 01, 2014 First Warning Systems, ... circadian cellular changes throughout the body, announced the company ... better address the company’s breadth of upcoming product releases. ... cancer screening technology. , “Our initial focus will be ... which detects abnormal circadian cellular changes over time,” said ...
(Date:10/1/2014)... Join the more than 80 golfers who ... first ever charity golf tournament to benefit Project HEAL, a ... who cannot afford treatment. The tournament will be held Monday, ... , The day-long event starts with 10:30 a.m. check-in ... dinner will begin at 5 p.m. and will include an ...
(Date:10/1/2014)... Innovations announces the upcoming airing of ... Monday, October 20, 2014 at 7:30 a.m. EST/PT via ... behind the scenes to learn about Break the Cycle’s ... the practical help and information Break the Cycle provides ... signs of abuse, how to navigate the legal system, ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... ... distribute Pluromed,s BackStop™ device, a rapid phase transition gel used in the treatment of ... ... entered into an alliance with Boston Scientific Corporation (NYSE: BSX) regarding Pluromed,s BackStop™ product, ...
... , ... California is pleased to announce its new relationship with La Maestra Community Health Centers of ... well as mammography screening reports for La Maestra and their patients. , ... Riverside, CA (PRWEB) October 8, 2009 ...
... Last Sunday, the Inland Community had one message as they ... With more than 6,000 walkers and raising more than $328,000, ... Annual Believe and Walk for the Cure was a ... , The sea of goodwill was overwhelming for the Co-Founders ...
... House and Senate leaders negotiate the final details of their ... that one provision under consideration, the Community Living Assistance Services ... Moreover, the long-term cost of this new entitlement, which could ... to produce a short-term windfall. , "The CLASS Act ...
... today announced the arrival of a new subject matter ... team member signifying continued growth of the Dallas-based health ... ) , Gregory R. Alperstein, ASA, MAAA joins the ... With more than 14 years of experience in the ...
... and mom-to-be Shannon Miller is the new spokesmom for BabyPlus®. ... and has been using BabyPlus during pregnancy to ensure her ... Now she,s sharing her experience and enthusiasm for BabyPlus ... http://www.newscom.com/cgi-bin/prnh/20091007/DE88885 ) , "We are thrilled to ...
Cached Medicine News:Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 2Health News:Pluromed, Inc. Signs Agreement with Boston Scientific 3Health News:ONRAD Announces New Partnership with La Maestra Community Health Centers of San Diego, CA 2Health News:Stater Bros. Charities Collects $328,000 for the Cure in 'I Believe Walk'... Over 6,000 Participate 2Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 2Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 3Health News:Concord Coalition Warns That New Entitlement Is Not a Valid Health Care Reform Offset 4Health News:Continued Growth Evident With New Hire and Promotion for Lockton Dunning Benefits 2Health News:Country's Most Decorated Gymnast New Spokesmom for BabyPlus 2
(Date:10/1/2014)... SAN DIEGO , Oct. 1, 2014  ResMed (NYSE: ... people sleep and the first company to design complete sleep ... to educate women about the importance of a good night,s ... initiative will challenge the myth that feeling tired is just ... to understand that sleep is a critical pillar of health, ...
(Date:10/1/2014)... --  Cypher Genomics, Inc., the genome informatics company, ... as chief technology officer. Ravenel has more than ... a proven track record of designing and architecting solutions ... been recognized as a top designer and architect of ... for delivering innovative products that operate at scale and ...
(Date:10/1/2014)... Calif. , Oct. 1, 2014 /PRNewswire/ ... ), a clinical-stage biopharmaceutical company focused on ... positive results from its 371 patient Phase ... with constipation-predominant irritable bowel syndrome (IBS-C).  Results ... clinically meaningful improvement in IBS-C symptoms for ...
Breaking Medicine Technology:ResMed Launches Initiative to Help Women Get Better Sleep 2ResMed Launches Initiative to Help Women Get Better Sleep 3Cypher Genomics Appoints J. Patrick Ravenel Chief Technology Officer 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
... Sept. 16 The American,Chemistry Council is aware ... today in,the Journal of the American Medical Association ... concentrations and medical,disorders in adults. As with any ... design of a study can limit interpretation of ...
... Biotech Begins to Demonstrate Strategy to Expand NHL ... Preclinical Development Program -, BRITISH COLUMBIA, Canada, ... OTC Bulletin Board: IXSBF;, http://www.ixsbio.com ), a drug ... based on its technology, Dynamic Cross,Linking (DXL(TM)), announced ...
Cached Medicine Technology:New Bisphenol A Study Has Limited Capability to Assess Human Health Effects 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 2InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies 3
... offered as 1-piece or modular, in regular ... may be customized with handles of choice ... and flush ports. Many standard patterns are ... affect delivery times. , Please Note: ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... special order products are offered as 1-piece ... lengths. The modular instruments may be customized ... such as ratchets, insulation and flush ports. ... stock. Customer specifications may affect delivery times. ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: